Here are the key takeaways:
1. Specifically, the FDA focused on disease outbreaks stemming from failures in compounding standards and injection practices.
2. Patients in outpatient oncology settings are at a higher risk for infection due to visiting multiple healthcare settings during treatment and for having indwelling intravascular access devices.
3. Infection control in outpatient oncology is often overlooked due to the lack of policies and procedures. As healthcare moves toward outpatient settings, infection control must be established and reinforced, the FDA said.
More articles on quality:
How palm-scanning tech can improve patient safety, prevent fraud: 3 key details
AORN recognizes 2 outpatient centers for surgical smoke-free facilities
Bacteria increasingly resistant to hand sanitizer in hospitals — 6 study findings in ‘Science Translational Medicine’
